20-F: MDxHealth Amends Asset Purchase Agreement, Secures Additional Capital

MDxHealth defers earn-out payments, increases potential consideration, and gains access to additional capital through an amended agreement with Genomic Health.

Summary

• MDxHealth and Genomic Health amended their Asset Purchase Agreement on August 23, 2023.
• The amendment defers the payment of the 2023 Earn-Out Amount to no later than fifteen (15) Business Days after January 1, 2027.
• As a result of the deferral, the total potential Earn-Out Consideration increased from $70,000,000 to $82,500,000.
• MDxHealth will provide additional consideration including $250,000 in cash, $877,500 as a payable contributed in kind by Seller to Buyer against the issuance by Buyer of 2,500,000 new Buyer Ordinary Shares, and the right to subscribe for 1,000,000 Buyer ADSs at $5.265 per ADS.
• Seller agrees and acknowledges that any of the Buyer Ordinary Shares to be delivered to the Seller in accordance with this Amendment (including the ADS Subscription Right) or underlying the Buyer ADSs to be issued in accordance with this Amendment (including the ADS Subscription Right) shall not be admitted to listing and trading on the regulated market Euronext Brussels until the Company shall have made the relevant filings and obtained the relevant approvals for such admission to listing and trading, and until such admission to listing and trading such Buyer Ordinary Shares shall be in registered form only.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While the deferral of payments could indicate short-term financial pressure, the increased potential earn-out and additional capital access suggest confidence in future growth. The complexity of the agreement warrants careful monitoring.

Positives

• MDxHealth gains flexibility by deferring the 2023 earn-out payment.
• The increased total potential earn-out consideration suggests confidence in future revenue growth.
• The right to subscribe for 1,000,000 Buyer ADSs at a price per ADS of $5.265 provides potential future capital.

Negatives

• The deferral of the earn-out payment implies potential short-term cash flow constraints for MDxHealth.
• The issuance of new shares dilutes existing shareholders' equity.
• The ADS Subscription Right is subject to shareholder approval.

Risks

• Buyer is unable to or does not, for whatever reason, issue the requisite ADSs or Ordinary Shares, then the Buyer shall pay to the Seller the Default Amount together with any reasonable costs and expenses incurred by the Seller in making full recovery of the consideration due in accordance with this Amendment.

Future Outlook

The agreement outlines potential earn-out payments through 2027, contingent on future business revenue.

Industry Context

This announcement reflects ongoing activity in the diagnostics industry, where companies often acquire assets or businesses to expand their product offerings and market reach.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The deferral of payments could impact Genomic Health's short-term revenue.
• The potential for increased revenue could benefit both companies in the long term.

Next Steps

• Consummation of the transactions contemplated by the Amendment.
• Issuance of Buyer Ordinary Shares and delivery of Buyer ADSs to the Seller.
• Convening an extraordinary general shareholders meeting to approve the issuance of the ADS Subscription Right to Seller.
• Buyer or any successor thereto shall enter into a registration rights agreement with Seller with respect to the registration of its securities in customary form and substance reasonably satisfactory to Seller and Buyer in connection with any future Public Offering.

Key Dates

Keywords

Asset Purchase Agreement, Earn-Out Consideration, Genomic Health, MDxHealth, Amendment, ADS, Capital